Objective: The objective of this study was to evaluate the efficacy of targeted intermittent fluconazole prophylaxis (FP) to high-risk preterm (PT) infants.
Introduction
Invasive fungal infections are a significant cause of morbidity and mortality among very low birth weight (VLBW) infants. 1 More than 30% of extremely low birth weight infants with candidemia die before discharge and 73% die or have neurodevelopmental impairment at 18 to 22 months corrected age. 1 Infants with candidiasis are more likely to have mental developmental index or psychomotor developmental index scores on the Bayley Scales of Infant Development of <70, more likely to have cerebral palsy and more likely to be blind or deaf as compared with neonates without fungal infections. 1 Apart from low gestational age, other recognized risk factors for invasive candidiasis include endotracheal intubation, parenteral nutrition, necrotizing enterocolitis (NEC), third-generation cephalosporins and central lines.
1,2 Preterm (PT) infants in the neonatal intensive care unit (NICU) are exposed to many of these risk factors for prolonged durations. For example, as many as 46% of VLBW infants have a percutaneous central catheter inserted at some time during their hospital stay. 3 Several studies have demonstrated that prophylactic fluconazole decreases fungal colonization and subsequent invasive fungal infection in PT infants. [4] [5] [6] [7] [8] The duration of prophylaxis in most of these studies is from 4 to 6 weeks, starting at birth to 3 days of age. 4, 5, 8 The risk of invasive candidiasis persists from birth to 3 months, with the highest risk reported to be between 11 and 20 days of life. 1 The approach of prophylaxis, from 4 to 6 weeks, to all extremely low birth weight infants treats a large number of infants for a prolonged duration, some of whom may be at low risk for infection. The emergence of fluconazole resistance in neonates remains as a potential concern, although it is exceedingly rare, probably due to the dosing and shorter duration of prophylaxis in neonates compared with adult studies. Over a 10-year period, a 1.1% incidence of native fluconazole-resistant systemic fungal infections was reported in one study and in two Candida parapsilosis isolates in another Finnish NICU. 4, 9 Nevertheless, fluconazole prophylaxis (FP) for all extremely low birth weight infants in the NICU is not yet standard of care, particularly in centers with low rates of invasive candidiasis. 10, 11 In an attempt to optimize benefits, we implemented an intermittent FP regimen for high-risk infants with multiple risk factors for invasive candidiasis. Our objective, in this study, was to compare the incidence and profile of invasive candidiasis before and after implementation of targeted FP. We also compared hematological laboratory measures and markers of hepatic and renal dysfunction among VLBW infants who received targeted FP and those who did not, during the FP time period. We hypothesized that targeted FP for VLBW infants with multiple risk factors will reduce the incidence of invasive fungal infections, while minimizing drug exposure.
Methods
This was an observational study with a pre-post cohort design. Institutional review board approval for the study and a waiver of parental consent was obtained. Before 2006, we did not use FP. In March 2006, we developed a 'targeted FP' protocol in our NICU in response to the high rates of candidiasis in our center. The protocol was based on an evidence-based review of the literature, and it addressed risk factors deemed important in our NICU. Extensive discussions among the medical, nursing and pharmacy staff were held before implementation of the protocol. For the purpose of this study, the 'FP period' was assigned from June 2006 to December 2007. The period between March and 1 June was when the protocol was disseminated to all the staff and they were allowed for acclimation to the new policy. The control period was from January 2005 to May 2006. The targeted fluconazole strategy was modified from existing literature and implemented as a quality improvement measure. Therefore, investigational new drug was not obtained and the protocol was not registered as a clinical trial.
Fluconazole prophylaxis was administered to selected infants (i.e., birth weight <1500 g and <6 weeks of age) who received broad-spectrum antibiotics for more than two consecutive days and had at least one of the following additional risk factors: a central venous catheter, endotracheal intubation, required parenteral nutrition or definite (modified Bells' stage 2 or higher) NEC. Targeted FP was administered concomitantly with broad-spectrum antibiotics and was initiated when a decision was taken to administer broad-spectrum antibiotics for longer than 48 h and it was stopped when the antibacterials were discontinued. Infants were excluded from prophylaxis if they had severe hepatic dysfunction defined as marked hepatomegaly, severe conjugated hyperbilirubinemia (direct bilirubin >5 mg dl À1 ) and serum transaminases (both alanine aminotransferase and aspartate aminotransferase) >150 IU l À1 on the most recent set of laboratories. A dose of 3 mg kg À1 was infused at intervals ranging from every 24 to 72 h, based on postmenstrual and postnatal age and standard recommendations. 12 We also follow a standardized treatment protocol for invasive candidiasis (cultures from blood or spinal fluid), broadly based on the Infectious Diseases Society of America recommendations; lipid complex amphotericin B (5 to 7.5 mg kg À1 per day) is a first-line therapy, and fluconazole (10 mg kg À1 per day) and micafungin (10 mg kg À1 ) are sequentially added if cultures remain positive despite 48 to 72 h of therapy. Following diagnosis of fungal bloodstream infection, daily or every other day blood cultures are drawn until a minimum of three negative cultures are obtained. Other culture sites include the central line, spinal fluid, urine and endotracheal tube in ventilated infants. An ophthalmological examination for fungal ophthalmitis and imaging studies, such as renal ultrasounds and echocardiograms, are routinely performed at the time of diagnosis, and repeated weekly in case of persistent infection. Throughout the 3-year period of the study, there were no changes in infection-control practices in our NICU. Ampicillin and gentamicin have been consistently used as initial empiric antibiotics for suspected early-onset sepsis, whereas a combination of vancomycin and a third-generation cephalosporin (cefotaxime or cefepime) are the therapeutic choices for suspected late-onset sepsis. Limited use of empiric antibiotics is encouraged, and the antibiotic choice is rotated periodically. All infants with methicillin-resistant staphylococcal infection from a sterile site (blood or spinal fluid), or eye, endotracheal or wound fluid are placed in an isolation pod with contact-isolation precautions.
A detailed medical record review was performed for all VLBW infants (birth weights <1500 g) admitted to the NICU between 1 January 2005 and 31 December 2007. These infants were identified using the electronic admission database at Hutzel Women's Hospital NICU. Demographic data, clinical characteristics and outcomes at discharge were abstracted. Outcomes were defined using standardized a priori definitions: bronchopulmonary dysplasia as oxygen need at 28 days and at 36-weeks postmenstrual age, using the National Heart, Lung and Blood Institute severitybased classification; NEC as modified Bell's staging stage 2 or higher; retinopathy of prematurity requiring intervention as retinopathy of prematurity stage 4 or stage 3 requiring laser therapy; bloodstream infection as culture-positive infections from the blood and patent ductus arteriosus as echocardiographically proven moderate or large-sized patent ductus arteriosus associated with clinical signs of hemodynamic significance. Each infant was evaluated to determine whether eligibility criteria for FP were met, and details of duration and the number of doses administered were collected. We described details of invasive candidiasis including age at diagnosis, the fungal species, duration of positive cultures and the number and type of antifungals administered. Invasive candidiasis was defined as isolation of candida in cultures from sterile sites such as blood or spinal fluid. Details of central catheters and the timing of removal after diagnosis of invasive fungal infection were also obtained. We abstracted weekly laboratory data on liver enzymes such as alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, blood urea nitrogen, serum creatinine, total and direct bilirubin and platelet counts for all infants in the FP period during the initial 6 weeks of life. If an infant had more than one value during a week, the highest value was recorded for each measure, except for platelets for which the lowest value was recorded. At our institution, we routinely monitor these values every week for all infants receiving any parenteral nutrition. Elevated direct bilirubin was defined as >5 mg dl À1 , hepatic impairment as alanine aminotransferase or aspartate aminotransferase>150U l À1 , elevated serum creatinine as >1 mg dl À1 and thrombocytopenia as platelet count <100 000 mm À3 . Statistical analysis was performed using SPSS version 17 (SPSS, Chicago, IL). Descriptive statistics included number (%), mean (s.d.) for normally distributed continuous variables and median (range) values, as appropriate. The group of VLBW infants admitted in the control period was compared with the group admitted in the 'targeted FP period', using Fisher's exact two-tailed test and t-test for proportions and continuous variables and w 2 -test for categorical variables. Bivariate regression analysis, incorporating Hosmer-Lemeshow goodness-of-fit test, was used to determine the association among clinical variables, including FP period with Candida bloodstream infection and/or meningitis. Regression analysis was also used to determine the association, whether any, among various laboratory abnormalities (elevated direct bilirubin, hepatic or renal impairment and thrombocytopenia), with clinical variables including fluconazole administration. P-value of <0.05 was considered statistically significant.
Results

Study cohort
Our study cohort consisted of 547 VLBW infants admitted to the NICU between January 2005 and December 2007. A total of 23 infants were transferred to a different hospital system and, therefore, were not included in our cohort, leaving 524 infants; 230 in the control period and 294 in the FP period. Supplementary Table 1 compares the demographic data, clinical characteristics and outcomes in the two groups (control and FP periods) of infants. The durations of total parenteral nutrition administration and central line in the first 6 weeks were higher in the FP period, whereas surfactant use was significantly lower. There was a significant rise in the rate of definite NEC.
Invasive candidiasis
The rate of invasive candidiasis decreased from 15.3% in the control period to 6.2% in the FP period (P ¼ 0.001). As shown in Table 1 , the number of C. albicans bloodstream infections decreased in the prophylaxis time period (24 to 10), whereas the number of C. parapsilosis stayed the same (6 to 7). There was a significant (P ¼ 0.002) decline in urinary tract infections from 10 (4.3%) cases to 1 (0.3%) case in the FP period. Of the infants with urinary tract infection, 7 had a concomitant bloodstream infection, all of whom were in the control period. Mean central line duration was significantly higher among infants with invasive candidiasis during the FP period (28.6 (10.1) vs 22.8 (9.1) days). Other baseline and infection-related characteristics and outcomes were comparable in the two time periods. The type of treatment between the two groups did differ significantly. In the fluconazole period, a greater proportion of infants received three antifungal medications, amphotericin, fluconazole and an echinocandin, either caspofungin or micafungin. On bivariate regression analysis, using time period, birth weight, total parenteral nutrition duration, central line duration, NEC and antibiotic duration as variables, lower birth weight (odds ratio (OR) 1.003; 95% confidence interval (CI) 1.001 to 1.005) was independently associated with invasive candidiasis, whereas shorter total parenteral nutrition duration (OR 0.87; 95% CI 0.83 to 0.92) and being admitted in the FP period (OR 0.19; 95% CI 0.09 to 0.4) were protective. Of the infants with invasive candidiasis, 24 (68.6%) in the control period and 13 (72.2%) in the fluconazole period met our criteria for prophylaxis. In the fluconazole period, before the invasive candidiasis episode, 10 of 13 infants actually received FP for a mean ( ± s.d.) duration of 2.7 ( ± 3.8) days and 1.4( ± 1.5) doses. We compared infants with invasive candidiasis who met criteria for ) and thrombocytopenia (platelet counts<100 000 mm
À3
). Fluconazole administration was defined as prophylaxis or therapy. Fluconazole administration was not significantly associated with any adverse laboratory marker. Elevated direct bilirubin was noted in the first 6 weeks in 22 infants; significant covariates were gestational age (OR 1.44; 95% CI 1.06 to 1.96, P ¼ 0.02) and shorter duration of antibiotics (OR 0.91; 95% CI 0.85 to 0.97, P ¼ 0.006). The risk of hepatic impairment (n ¼ 22) tended to be lower in those without definite NEC (OR 0.26; 95% CI 0.06 to 1.08, P ¼ 0.06). Renal impairment (n ¼ 83) and thrombocytopenia (n ¼ 120) were significantly associated with lower gestation (OR 2.05; 95% CI 1.62 to 2.6, P ¼ 0.0001 and OR 1.16; 95% CI 1.04 to 1.29, P ¼ 0.006).
Discussion
Using highly selective criteria and an intermittent FP regimen, we demonstrated a significant reduction in the incidence of invasive candidiasis at our center, compared with a historical control Abbreviation: FP, fluconazole prophylaxis. All percentage is within the subgroup.
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period. With our approach, all VLBW infants were evaluated for a prolonged period of 6 weeks but were eligible for FP only if they were administered broad-spectrum antibiotics and had at least one additional risk factor, and that too, only for the duration of antibiotic administration. On further scrutiny, all infants who were administered FP were on parenteral nutrition at the time of initiation of prophylaxis. A simplification of our criteria to include broad-spectrum antibiotics and the need for parenteral nutrition, would, therefore, have captured all identified infants. A reduction in invasive candidiasis with FP has been previously demonstrated in multiple randomized controlled trials and retrospective cohort studies. [5] [6] [7] [8] 13 Limited studies using a more targeted approach of prophylaxis to select high risk groups have reported success. Uko et al.
14 reported the efficacy of targeted short-term prophylaxis during discrete periods of antibiotic administration in reducing invasive fungal infection, in comparison with a historic control who did not receive any prophylaxis. The OR for invasive fungal infection was similar to 4-to 6-week fluconazole courses, with a lower number of doses (median 6) per infant; 51% of all VLBW infants received prophylaxis. Weitkamp et al. 15 used a targeted approach of FP to 42 PT infants (<750 g birth weight or <26 weeks gestational age with a central line access) for 6 weeks, and again demonstrated a reduction in invasive fungal infections, compared with historic controls. In our center, the mean birth weight and gestational age of infants with invasive candidiasis in the control period was 786 g and 26 weeks, respectively. A cutoff of birth weight <750 g, would, therefore, exclude many at-risk infants likely to benefit from prophylaxis. Using our protocol of additional risk factors and broad-spectrum antibiotics, we limited FP eligibility from 28 to 40% of VLBW infants. About 30% of the infants with invasive candidiasis in both the time periods, however, did not meet our criteria for FP. Apart from a significantly shorter duration of antibiotics and less NEC, these infants had an early age of onset of invasive candidiasis. These results lead us to speculate on an antenatal or intrapartum origin of invasive fungal infection in a proportion of PT infants. A strategy of early FP for PT infants for 2 to 3 weeks, followed by further 'targeted prophylaxis' in the presence of multiple risk factors may be required in such cases.
We noted a significant increase in the rate of NEC during the FP period, in comparison with the control period. On detailed analyses, in all but two cases, NEC predated FP, which was started during the broad-spectrum antibiotic administration for NEC therapy. Although the increase was statistically significant, the NEC rate was still within the reported incidence range (4 to 11%) for PT infants <1500 g birth weight in the NICHD Neonatal Research Network centers. 16 As in most other prophylaxis studies, we were unable to demonstrate a significant difference in overall mortality rates with the implementation of targeted FP. 17 In previous studies, an association between FP and a higher incidence of cholestasis, as well as reversible elevations in liver enzymes and bilirubin levels have been reported. 13, 18 Healy et al.
19
had also described a shift of invasive candidiasis to older, more mature infants after implementation of FP for extremely low birth weight infants. On a careful evaluation of laboratory results over the initial 6 weeks, FP was not independently associated with elevated direct jaundice, liver enzymes, thrombocytopenia or elevated serum creatinine. Mean direct bilirubin was well below 5 mg dl À1 and mean platelet counts were above 100 000 mm À3 through the 6 weeks in both the groups. In addition, the numbers of infants with elevated direct bilirubin or liver enzymes were low (22 of 274). The gestational age of infants who developed invasive candidiasis and age at onset of the infection were similar in the two time periods. In addition, although the proportion of C. parapsilosis infections increased in the fluconazole phase, infections by other fluconazole-resistant species such as C. glabrata and C. krusei decreased.
We recognize several limitations of our study. The biggest is the historical control, which may have potentially overestimated the effect size. 20 Only 75% of infants who met eligibility criteria for fluconazole received it. This rate is lower than what we would have hoped, and it underscores the importance of regular training of clinicians or a computerized trigger for successful implementation of complex protocols. A simplification of eligibility criteria to broad-spectrum antibiotics and the need for parenteral nutrition would, perhaps, also improve compliance rates. We, similar to other studies on FP, had a high rate (15%) of Candida bloodstream infections and/or meningitis in the control period. Rates of invasive candidiasis in two randomized controlled trials and one targeted retrospective study ranged from 13.2 to 20%. 6, 13, 15 A much lower incidence of 7% Candida bloodstream infections is reported among the NICHD Neonatal Research Network centers for PT infants with birth weights <1000 g. 1 According to the National Mycoses Study Group, 3.1% of VLBW (<1500 g) infants develop Candida bloodstream infections, whereas a 1% rate were reported in the UK prospective surveillance study. 21, 22 Whether our results can be extrapolated to other centers with low rates remains to be determined. Our approach of intermittent fluconazole for a few doses to only a third of VLBW infants may, however, be most attractive to centers with low rates of candidiasis.
In conclusion, we used a minimalistic approach of an intermittent FP regimen, typically a few doses, to a highly selected population of high-risk PT VLBW infants. Although limited by a historic control design, we showed reduced drug exposure and a significant reduction in invasive candidiasis. There were no overt adverse effects, and the profile of invasive candidiasis, the age and population affected and the fungal species distribution remained relatively unchanged. Further investigation aimed at individualized risk stratification, and evaluation of the long-term neurodevelopmental effects of a customized FP strategy is warranted.
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